سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Doroudinia, Abtin, Emami, Hadi, Hoseini, Mahsa. (1400). 68Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study. , 10(1), 14-19. doi: 10.22038/aojnmb.2021.56971.1397
Abtin Doroudinia; Hadi Emami; Mahsa Hoseini. "68Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study". , 10, 1, 1400, 14-19. doi: 10.22038/aojnmb.2021.56971.1397
Doroudinia, Abtin, Emami, Hadi, Hoseini, Mahsa. (1400). '68Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study', , 10(1), pp. 14-19. doi: 10.22038/aojnmb.2021.56971.1397
Doroudinia, Abtin, Emami, Hadi, Hoseini, Mahsa. 68Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study. , 1400; 10(1): 14-19. doi: 10.22038/aojnmb.2021.56971.1397

68Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study

Asia Oceania Journal of Nuclear Medicine and Biology
مقاله 2، دوره 10، شماره 1، فروردین 2022، صفحه 14-19    اصل مقاله (337.29 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/aojnmb.2021.56971.1397
نویسندگان
Abtin Doroudinia؛ Hadi Emami؛ Mahsa Hoseini*
Chronic Respiratory Diseases Research Center, National research institute of tuberculosis and lung diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Objevtive(s): Neuroendocrine tumors are a heterogeneous group of neoplasms that arise from the peptide-producing cells of the neuroendocrine system. Different functional imaging methods have been suggested to diagnose NETs. There is still not enough evidence to recommend 68Ga-DOTATATE as a standard diagnostic tool in NETs. Therefore, the aim of this study was to assess the value of 68Ga-DOTATATE scan in detecting NETs.
Methods: This was a cross-sectional study. All patients with a pathologically confirmed NET tumor referred to Masih Daneshvari Hospital affiliated to Shahid Beheshti University of Medical Sciences entered the study. Patients underwent a 68Ga-DOTATATE PET/CT. All statistical analysis were performed by SPSS software version 18.
Results: Forty patients with a mean age of 48.1±15.80 years entered the study. Twenty-one (52.5%) were male and 19 (47.5%) female. In the studied patients, neuroendocrine tumor was present in 19 cases (47.5%) in pancreas and gastrointestinal tract, 9 (22.5%) in lung, 3 (7.5%) in mediastinum and adrenal gland, 6 cases (5%) in liver and 3 other sites. There was no significant association between mean age and gender with primary location of the tumor. The mean
SUVmax was 11.62±20.02 and the the mean tumor size was 38.25±31.35 mm. The mean size of the metastasis was 40.55±24.53 mm. The mean percentage of ki-67 was 12.54±18.40. There was no significant correlation between SUVmax of the lesion and age (r=0.063, P=0.701), tumor size (r=-0.63, P=0.067) or Ki-67 (r=0.011, P=0.960). In 20 cases, metastases were reported, of which 14 were (70%) in the liver, 3 in the lungs (15%), 2 in the gastrointestinal and cervical lymph nodes, and 1 in the bones and pancreas(%5).
Conclusion:68Ga-DOTA-peptide PET/CT could find the primary or metastasis sites of NETs with good quality images. In general, this modality can enhance the management in patients with NETs.
کلیدواژه‌ها
68Ga-DOTA-peptide PET/CT؛ Neuroendocrine tumors؛ Diagnosis
مراجع
  1. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, et al. Neuro-endocrine tumors. Journal of the National Comprehensive Cancer Network. 2012; 10(6):724-64.
  2. Clark OH, Ajani JA, Benson AB, Berlin JD, Blaszkowsky LS, Byrd D, et al. Neuro-endocrine tumors. JNCCN Journal of the National Comprehensive Cancer Network. 2009; 7(7):712-47.
  3. Cejas P, Drier Y, Dreijerink KM, Brosens LA, Deshpande V, Epstein CB, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nature medicine. 2019; 25(8):1260-5.
  4. The Chicago consensus on peritoneal surface malignancies: management of neuroendocrine Annals of surgical oncology. 2020:1-5.
  5. Barthet M, Giovannini M, Lesavre N, Boustiere C, Napoleon B, Koch S, et al. Endoscopic ultrasound-guided radio-frequency ablation for pancreatic neuro-endocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019; 51(09):836-42.
  6. Lv Y, Han X, Xu X-F, Ji Y, Zhou Y-H, Sun H-C, et al. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroentero-pancreatic neuroendocrine tumors after initial R0 surgical resection. BMC cancer. 2019; 19(1):1-9.
  7. Mazzaferro V, Pulvirenti A, Coppa J. Neuro-endocrine tumors metastatic to the liver: how to select patients for liver trans-plantation? Journal of hepatology. 2007; 47(4):460-6.
  8. De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somato-statin analogues. Accounts of chemical research. 2009; 42(7):873-80.
  9. Krenning E, Kwekkeboom DJ, Bakker Wea, Breeman W, Kooij P, Oei H, et al. Somatostatin receptor scintigraphy with [111 In-DTPA-D-Phe 1]-and [123 I-Tyr 3]-octreotide: the Rotterdam experience with more than 1000 patients. European journal of nuclear medicine. 1993; 20(8):716-31.
  10. Simons ZB, Wangsiricharoen S, Gelwan E, Lilja SB, Santhanam P. SUN-904 Ga68 Dotatate Detects Ectopic ACTH Secreting Atypical Carcinoid Tumor. Journal of the Endocrine Society. 2020; 4(Supplement_1): SUN-904.
  11. Hofman MS, Lau WE, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015; 35(2):500-16.
  12. Guenter R, Aweda T, Matos DMC, Jang S, Whitt J, Cheng Y-Q, et al. Overexpression of somatostatin receptor type 2 in neuro-endocrine tumors for improved Ga68-DOTATATE imaging and treatment. Surgery. 2020; 167(1):189-96.
  13. Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines The Journal of Clinical Endocrinology & Metabolism. 2015; 100 (11):E1437-E45.
  14. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radio-labelled somatostatin analogues. European journal of nuclear medicine and molecular imaging. 2005; 32(10):1136-43.
  15. Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, et al. DOTA− d-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy. Bioconjugate chemistry. 2002; 13(4):721-8.
  16. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica. 2007; 46(6):723-34.
  17. Bombardieri E, Maccauro M, de Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Annals of Oncology. 2001; 12:S51-S61.
  18. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017; 44(9):1588-601.
  19. Gustafsson BI, Kidd M, Modlin IM. Neuro-endocrine tumors of the diffuse neuro-endocrine system. Current opinion in oncology. 2008; 20(1):1-12.
  20. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastro-enteropancreatic neuroendocrine tumours. The lancet oncology. 2008; 9(1): 61-72.
  21. Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, et al. Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. Journal of Surgical Oncology. 2020; 121(3):480-5.
  22. Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, et al. Neuroendocrine tumours of the GI tract--data from the German NET Registry. Zentralblatt furChirurgie. 2012; 139(3):276-83.
  23. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012; 56(1):40-7.
  24. Özkan ZG, Kuyumcu S, Balköse D, Ozkan B, Aksakal N, Yılmaz E, et al. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors.Mol Imaging Radionucl Ther. 2013; 22(2): 49-55.
  25. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/ computed tomography on the multimodal management of patients with neuro-endocrine tumors. Annals of surgery. 2010; 252(5):850-6.
  26. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014; 55(4):389-98.
  27. Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, et al. 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First US Prospective, Reader-Masked Clinical Trial. Journal of Nuclear Medicine. 2020; 61(6):890-6.
آمار
تعداد مشاهده مقاله: 987
تعداد دریافت فایل اصل مقاله: 397